I am a
Home I AM A Search Login

Papers of the Week

2022 Feb 10

Curr Oncol



Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.


Dang E, Vallée A, Lepage-Seydoux C, Sejean K, Bonan B, Abraham C, Beuzeboc P, Ratta R
Curr Oncol. 2022 Feb 10; 29(2):945-955.
PMID: 35200579.


Pembrolizumab is approved for patients with metastatic urothelial carcinoma (UC) who progressed under platinum therapy. The aim of this study was to assess the efficacy and safety of pembrolizumab in a cohort of real-life UC patients.